Phase I/II study of cediranib and olaparib in combination for treatment of recurrent platinum-sensitive papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent triple-negative breast cancer

Trial Profile

Phase I/II study of cediranib and olaparib in combination for treatment of recurrent platinum-sensitive papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent triple-negative breast cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary)
  • Indications Advanced breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 26 May 2017 According to an AstraZeneca media release, data from this study will be presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
    • 25 Oct 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top